Partillion Bioscience Corporation, a Los Angeles, CA-based life science tools company, raised $5M in Seed funding.
Backers included ND Capital, Vertical Venture Partners, and Paladin Capital. Eric Moessinger, Partner at ND Capital, Paul Conley, former board member at 10X Genomics and Twist Bioscience, and CEO of General Inception, and Brad Crutchfield, formerly Chief Commercial Officer at 10X Genomics and President of Bio-Rad’s Life Science Group, joined its board.
The company intends to use the funds to accelerate its growth and launch new functional single-cell analysis and sorting product lines enabled by its proprietary Nanovial technology.
Led by CEO Joe de Rutte, Partillion Bioscience is a life science company developing a single-cell analysis platform. Its Nanovial technology enables customers to accelerate therapeutic development to address the most difficult diseases and provide advanced scientific insights. The reagent-based platform, with products available at www.partillion.com, unlocks the ability to screen individual cells based on difficult to probe functional information all while using easy to access lab equipment – solving a major pain point in the industry.
The technology underpinning Partillion’s products was developed in Dino Di Carlo’s lab (UCLA).
FinSMEs
27/09/2023